/BCAB
BCAB Stock - BioAtla, Inc.
Healthcare|BiotechnologyNASDAQ
$0.75-4.89%
$0.04 (-4.89%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.71
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+563.7%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BCAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.75 – $0.76
TARGET (TP)$5.00
STOP LOSS$0.69
RISK/REWARD1:67.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.00
52W High$1.43
52W Low$0.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $11.00M | N/A | N/A | $250,000 | $429,000 |
| Gross Profit | $10.07M | $-1,221,000 | $-1,199,000 | $250,000 | $-19,504,000 |
| Gross Margin | 91.6% | N/A | N/A | 100.0% | -4546.4% |
| Operating Income | $-73,943,000 | $-129,687,000 | $-108,140,000 | $-96,440,000 | $-30,099,000 |
| Net Income | $-69,776,000 | $-123,462,000 | $-105,283,000 | $-95,402,000 | $-35,853,000 |
| Net Margin | -634.3% | N/A | N/A | -38160.8% | -8357.3% |
| EPS | $-1.44 | $-2.58 | $-2.74 | $-2.76 | $-1.06 |
Company Overview
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$11
Average Target
↑ 1360.0% Upside
Now
$5
Low
$11
Average
$17
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 13th 2025 | Citizens JMP | Downgrade | Market Perform | - |
| November 13th 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| September 15th 2022 | JMP Securities | Initiation | Mkt Outperform | $17 |
| May 5th 2022 | Credit Suisse | Downgrade | Neutral | $5← $35 |
Earnings History & Surprises
BCABBeat Rate
68%
Last 19 quarters
Avg Surprise
+5.3%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q1 24
+29.1%
$-0.56vs$-0.79
Q2 24
+15.8%
$-0.48vs$-0.57
Q3 24
+2.2%
$-0.44vs$-0.45
Q4 24
+35.3%
$-0.22vs$-0.34
Q1 25
+20.0%
$-0.32vs$-0.40
Q2 25
-3.6%
$-0.29vs$-0.28
Q3 25
-6.9%
$-0.31vs$-0.29
Q4 25
+12.9%
$-0.27vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.36 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.29 | $-0.31 | -6.9% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.28 | $-0.29 | -3.6% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.40 | $-0.32 | +20.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.34 | $-0.22 | +35.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.45 | $-0.44 | +2.2% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.57 | $-0.48 | +15.8% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-0.79 | $-0.56 | +29.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.77 | $-0.70 | +9.1% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.64 | $-0.75 | -17.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.66 | $-0.58 | +12.1% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.74 | $-0.63 | +14.9% | ✓ BEAT |
Q4 2022 | Nov 4, 2022 | $-0.77 | $-0.69 | +10.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.70 | $-0.77 | -10.0% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.69 | $-0.65 | +5.8% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.72 | $-0.63 | +12.5% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.92 | $-0.68 | +26.1% | ✓ BEAT |
Q3 2021 | Aug 13, 2021 | $-0.56 | $-0.90 | -60.7% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-0.52 | $-0.56 | -7.7% | ✗ MISS |
Latest News
BioAtla Secures $7.5M Advance And Up To $15M Standby Equity Commitment To Support Strategic Transaction
📈 PositiveBenzinga•Nov 21, 2025, 07:44 AM
BioAtla Q3 EPS $(0.27) Beats $(0.30) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:10 PM
BioAtla Presents Clinical Data In Poster Titled "Median OS Of 21.5 Months Among 44 Patients With Treatment-Refractory Leiomyosarcoma, Liposarcoma, And Undifferentiated Pleomorphic Sarcoma Treated With Mecbotamab Vedotin, An AXL-Targeting ADC," At SITC 2025
📈 PositiveBenzinga•Nov 7, 2025, 02:12 PM
BioAtla Presents Ozuriftamab Vedotin Clinical Data Targeting ROR2 In HPV+ Head & Neck Cancer at IPVS Conference 2025
➖ NeutralBenzinga•Oct 23, 2025, 12:17 PM
BioAtla shares are trading lower. The company announced preliminary clinical data from a Phase 1 study of BA3182 during a poster presentation titled "Preliminary Results from a First-in-Human Phase 1 Study of BA3182, a Dual-Conditionally Binding Biologic (CAB) EpCAM x CD3 Bispecific T-cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma" at the European Society for Medical Oncology Congress 2025
📉 NegativeBenzinga•Oct 20, 2025, 01:24 PM
BioAtla Releases Phase 1 Data For Its Investigational Therapy BA3182 Showing Manageable Safety With Only Two Cases Of Cytokine Release Syndrome ,Prolonged Tumor Control Including A Confirmed Partial Response In A Patient With Intrahepatic Cholangiocarcinoma Lasting Over Six Months, And No Defined Maximum Tolerated Dose
📈 PositiveBenzinga•Oct 20, 2025, 12:08 PM
BioAtla Will Present Clinical Data For Its Investigational Axl-Targeting Antibody-Drug Conjugate Mecbotamab Vedotin At The SITC 2025 Annual Meeting
📈 PositiveBenzinga•Oct 3, 2025, 01:03 PM
BioAtla shares are trading higher after the company announced regulatory update on its clinical development plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma following its Type B meeting with the FDA.
📈 PositiveBenzinga•Sep 8, 2025, 04:15 PM
BioAtla Highlights FDA Alignment On Phase 3 Ozuriftamab Vedotin Trial Design; Says Co Continues Preparations For Enabling Initiation Of Phase 3 Study; Co Maintains Previous Guidance
📈 PositiveBenzinga•Sep 8, 2025, 12:07 PM
Frequently Asked Questions about BCAB
What is BCAB's current stock price?
BioAtla, Inc. (BCAB) is currently trading at $0.75 per share. The stock has moved -4.89% today.
What is the analyst price target for BCAB?
The average analyst price target for BCAB is $5.00, based on 1 analyst.
What sector is BioAtla, Inc. in?
BioAtla, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BCAB's market cap?
BioAtla, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does BCAB pay dividends?
No, BioAtla, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
MURA
Mural Oncology plc
$2.04
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
VERU
Veru Inc.
$2.32
Mkt Cap: $0.0B
Explore stocks similar to BCAB for comparison